Zhongjin: The trend of investment in the innovative pharmaceutical industry is clear, and there may be opportunities to lead or have industrial chain opportunities.

A report from Zhongjin Securities Research stated that, in the long term, Chinese innovative drugs have entered a progressive innovation era with international competitiveness after following the innovation accumulation. In the medium term, competitive clinical data and BD issues with multinational corporation partnerships are important catalysts. In the short term, important data disclosure at academic conferences like ASCO/ESMO, BD announcements, and international breakthroughs bring stock price elasticity. At the same time, the convenience of first-tier and second-tier financing, as well as the slowdown in the international situation, bring investment opportunities in the industry chain, CXO, research and development, and other related areas.